Cite
HARVARD Citation
Han, J. et al. (n.d.). LBA2TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI. Annals of oncology. p. . [Online].